The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.

par Canney, P. A., Dowsett, M., Priestman, T. J.
Publié 1988

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.

par Canney, P. A., Moore, M., Wilkinson, P. M., James, R. D.
Publié 1984

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.

par Canney, P. A., Wilkinson, P. M., James, R. D., Moore, M.
Publié 1985

Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?

par Jodrell, D. I., Murray, L. S., Reed, N. S., Canney, P. A., Kaye, S. B., Cassidy, J.
Publié 1994

Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.

par Bissett, D., Jodrell, D., Harnett, A. N., Habeshaw, T., Kaye, S. B., Evans, D., Williams, M., Canney, P. A.
Publié 1995

Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer

par Murri, A M Al, Bartlett, J M S, Canney, P A, Doughty, J C, Wilson, C, McMillan, D C
Publié 2006

A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.

par Dhokia, B., Canney, P. A., Pectasides, D., Munro, A. J., Moore, M., Wilkinson, P. M., Self, C., Epenetos, A. A.
Publié 1986

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

par Awada, A, Albanell, J, Canney, P A, Dirix, L Y, Gil, T, Cardoso, F, Gascon, P, Piccart, M J, Baselga, J
Publié 2008

A phase II, multicentre, UK study of vinorelbine in advanced breast cancer.

par Twelves, C. J., Dobbs, N. A., Curnow, A., Coleman, R. E., Stewart, A. L., Tyrrell, C. J., Canney, P., Rubens, R. D.
Publié 1994

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.

par Ridge, S. A., Sludden, J., Wei, X., Sapone, A., Brown, O., Hardy, S., Canney, P., Fernandez-Salguero, P., Gonzalez, F. J., Cassidy, J., McLeod, H. L.
Publié 1998

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

par Jones, A L, Barlow, M, Barrett-Lee, P J, Canney, P A, Gilmour, I M, Robb, S D, Plummer, C J, Wardley, A M, Verrill, M W
Publié 2009

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

par Mackean, M. J., Cassidy, J., Jodrell, D. I., Paul, J., Reed, N. S., Canney, P. A., Yosef, H., Habeshaw, T., Robertson, A. G., McInnes, A., Twelves, C. J.
Publié 1998

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk bre...

par Thomas, J. S., Hanby, A. M., Russell, N., van Tienhoven, G., Riddle, K., Anderson, N., Cameron, D. A., Bartlett, J. M. S., Piper, T., Cunningham, C., Canney, P., Kunkler, I. H.
Publié dans Breast Cancer Res Treat (2017)